Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsThe proxy statement of Harmony Biosciences Holdings, Inc. reports total compensation of $5,732,705 for Kumar Budur in fiscal 2024, including a base salary of $555,147. Disclosed compensation is on record for 2 fiscal years. Kumar Budur has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Harmony Biosciences Holdings, Inc. on November 4, 2026. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member) and 7 others.
“We continue to make good progress across our robust clinical state pipeline, including five phase three registrational studies in five distinct rare neurological disorders, and BP-205, our potential best-in-class RxN2 receptor agonist.”
“So the new formulation of pedolescent, if we take a step back and look at fatigue in general, this is something that we have been thinking about for a while now.”
Proxy statement
Start not stated–present
Last confirmed April 4, 2025
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Medical & Scientific Officer | $555,147 | $5,732,705 |
| 2023 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Medical & Scientific Officer | $440,251 | $760,813 |
